Entry - #212070 - CARBOXYPEPTIDASE N DEFICIENCY; CPND - OMIM

# 212070

CARBOXYPEPTIDASE N DEFICIENCY; CPND


Phenotype-Gene Relationships

Location Phenotype Phenotype
MIM number
Inheritance Phenotype
mapping key
Gene/Locus Gene/Locus
MIM number
10q24.2 Carboxypeptidase N deficiency 212070 AR 3 CPN1 603103
Clinical Synopsis
 

INHERITANCE
- Autosomal recessive
HEAD & NECK
Face
- Facial swelling
Mouth
- Swelling of lips
- Swelling of tongue
RESPIRATORY
Larynx
- Laryngeal edema
Airways
- Airway occlusion (in some patients)
- Asthma
ABDOMEN
Gastrointestinal
- Abdominal angioedema
SKELETAL
Hands
- Swelling of the hands
Feet
- Swelling of the feet
SKIN, NAILS, & HAIR
Skin
- Angioedema, episodic
- Urticaria
MUSCLE, SOFT TISSUES
- Angioedema, episodic
IMMUNOLOGY
- Asthma
- Ragweed hay fever
- Elevated IgE levels
LABORATORY ABNORMALITIES
- Normal plasma C1NH (606860) levels
- Low carboxypeptidase-N (CPN1, 603103) levels
MISCELLANEOUS
- Onset in second or third decade (in most patients)
- Episodes may be spontaneous or in response to various triggers (oral contraceptives, stress, fatigue, mechanical pressure, cold temperature)
- Heterozygous family members also show low CPN1 levels and are symptomatic (generally to a lesser degree)
MOLECULAR BASIS
- Caused by mutation in the carboxypeptidase-N, polypeptide-1 gene (CPN1, 603103.0001)

TEXT

A number sign (#) is used with this entry because of evidence that carboxypeptidase-N deficiency (CPND) is caused by homozygous or compound heterozygous mutation in the CPN1 gene (603103) on chromosome 10q24.


Description

Carboxypeptidase-N deficiency (CPND) is an autosomal recessive disorder characterized by episodic angioedema, acute or chronic urticaria, asthma, and/or allergic hypersensitivities such as hay fever. Homozygous individuals as well as their heterozygous family members have levels of carboxypeptidase N that are below the reference range, and heterozygotes are symptomatic, albeit to a generally milder degree (Mathews et al., 1980; Vincent et al., 2024).


Clinical Features

Carboxypeptidase N is a serum alpha globulin metalloenzyme that inactivates C3a, C4a, C5a, bradykinin, kallidin, and fibrinopeptides. Mathews et al. (1980) found a low level of this enzyme (21% of normal) in a 65-year-old man with an 11-year history of episodic angioedema occurring about 40 times a year. The attacks, which lasted about 24 hours, most often involved the face and tongue but sometimes involved larger areas of pruritic, red swellings on the trunk or limbs. The proband's affected sister, who had a history of angioedema of the lips, acute urticaria of unknown cause, and asthma, had an equally depressed level of enzyme activity. Six children of these 2 sibs had intermediate levels consistent with heterozygous status. Multiple members of the family had allergic manifestations, i.e., angioedema/chronic urticaria, hay fever/asthma, or both.

Vincent et al. (2024) reported 4 unrelated families (A, B, C, and D) with hereditary angioedema (HAE) and mutation in the CPN1 gene. The probands in families A and B presented with recurrent urticaria and peripheral angioedema, triggered in the family A proband after stimulation for in vitro fertilization, whereas onset in the family B proband occurred while she was on oral contraceptives. The proband in family C had recurrent urticaria and abdominal symptoms that were resistant to H1 antihistamines, and the proband in family D presented with cold urticaria and H1 antihistamine-resistant angioedema. All 4 families included relatives who experienced similar symptoms. An urticarial rash accompanied nearly 60% of symptomatic episodes of angioedema.


Molecular Genetics

By sequencing the CPN1 gene in genomic DNA extracted from cells of the index patient reported by Mathews et al. (1980), Cao and Hegele (2003) demonstrated that the allergic manifestations in this family were due to presumed compound heterozygosity for 2 mutations in the CPN1 gene (see 603103.0001 and 603103.0002).

In the probands from 4 unrelated families with hereditary angioedema and urticaria, Vincent et al. (2024) identified biallelic mutations in the CPN1 gene. Probands B, C, and D were homozygous for the previously reported missense mutation G178D (603103.0002), whereas the proband in family A was compound heterozygous for G178D and a T245M substitution (603103.0003). Symptomatic family members who were tested were all heterozygous for the G178D mutation. Proband C and her affected mother and sister were also heterozygous for synonymous mutations in the CPN1 gene. In addition, symptomatic individuals in 3 of the families (A, B, and C) were reported to carry 1 or more variants in other kinin-associated genes; the relationship of the variants to the hereditary angioedema phenotypes in those families was unclear.


REFERENCES

  1. Cao, H., Hegele, R. A. DNA polymorphism and mutations in CPN1, including the genomic basis of carboxypeptidase N deficiency. J. Hum. Genet. 48: 20-22, 2003. [PubMed: 12560874, related citations] [Full Text]

  2. Mathews, K. P., Curd, J. G., Hugli, T. E. Decreased synthesis of serum carboxypeptidase N (SCPN) in familial SCPN deficiency. J. Clin. Immun. 6: 87-92, 1986. [PubMed: 3958137, related citations] [Full Text]

  3. Mathews, K. P., Pan, P. M., Gardner, N. J., Hugli, T. E. Familial carboxypeptidase N deficiency. Ann. Intern. Med. 93: 443-445, 1980. [PubMed: 7437116, related citations] [Full Text]

  4. Mathews, K. P. Deficiencies in regulator proteins. 4. Anaphylatoxin inactivator. Prog. Allergy 39: 344-351, 1986. [PubMed: 3562474, related citations]

  5. Vincent, D., Parsopoulou, F., Martin, L., Gaboriaud, C., Demongeot, J., Loules, G., Fischer, S., Cichon, S., Germenis, A. E., Ghannam, A., Drouet, C. Hereditary angioedema with normal C1 inhibitor associated with carboxypeptidase N deficiency. J. Allergy Clin. Immun. Glob. 3: 100223, 2024. Note: Erratum: J. Allergy Clin. Immun. Glob. 3: 100319, 2024. [PubMed: 38445235, images, related citations] [Full Text]


Marla J. F. O'Neill - updated : 09/23/2024
Victor A. McKusick - updated : 2/11/2003
Victor A. McKusick - updated : 2/4/1997
Creation Date:
Victor A. McKusick : 6/3/1986
alopez : 10/01/2024
alopez : 09/23/2024
alopez : 09/23/2024
alopez : 09/23/2024
carol : 02/21/2003
tkritzer : 2/13/2003
terry : 2/11/2003
alopez : 7/27/1999
alopez : 10/8/1998
alopez : 10/8/1998
alopez : 8/18/1998
mark : 2/5/1997
jenny : 2/4/1997
terry : 1/21/1997
mimadm : 2/19/1994
carol : 10/15/1992
carol : 9/4/1992
supermim : 3/16/1992
supermim : 3/20/1990
ddp : 10/26/1989

# 212070

CARBOXYPEPTIDASE N DEFICIENCY; CPND


SNOMEDCT: 124493003, 234627009;   DO: 0111583;  


Phenotype-Gene Relationships

Location Phenotype Phenotype
MIM number
Inheritance Phenotype
mapping key
Gene/Locus Gene/Locus
MIM number
10q24.2 Carboxypeptidase N deficiency 212070 Autosomal recessive 3 CPN1 603103

TEXT

A number sign (#) is used with this entry because of evidence that carboxypeptidase-N deficiency (CPND) is caused by homozygous or compound heterozygous mutation in the CPN1 gene (603103) on chromosome 10q24.


Description

Carboxypeptidase-N deficiency (CPND) is an autosomal recessive disorder characterized by episodic angioedema, acute or chronic urticaria, asthma, and/or allergic hypersensitivities such as hay fever. Homozygous individuals as well as their heterozygous family members have levels of carboxypeptidase N that are below the reference range, and heterozygotes are symptomatic, albeit to a generally milder degree (Mathews et al., 1980; Vincent et al., 2024).


Clinical Features

Carboxypeptidase N is a serum alpha globulin metalloenzyme that inactivates C3a, C4a, C5a, bradykinin, kallidin, and fibrinopeptides. Mathews et al. (1980) found a low level of this enzyme (21% of normal) in a 65-year-old man with an 11-year history of episodic angioedema occurring about 40 times a year. The attacks, which lasted about 24 hours, most often involved the face and tongue but sometimes involved larger areas of pruritic, red swellings on the trunk or limbs. The proband's affected sister, who had a history of angioedema of the lips, acute urticaria of unknown cause, and asthma, had an equally depressed level of enzyme activity. Six children of these 2 sibs had intermediate levels consistent with heterozygous status. Multiple members of the family had allergic manifestations, i.e., angioedema/chronic urticaria, hay fever/asthma, or both.

Vincent et al. (2024) reported 4 unrelated families (A, B, C, and D) with hereditary angioedema (HAE) and mutation in the CPN1 gene. The probands in families A and B presented with recurrent urticaria and peripheral angioedema, triggered in the family A proband after stimulation for in vitro fertilization, whereas onset in the family B proband occurred while she was on oral contraceptives. The proband in family C had recurrent urticaria and abdominal symptoms that were resistant to H1 antihistamines, and the proband in family D presented with cold urticaria and H1 antihistamine-resistant angioedema. All 4 families included relatives who experienced similar symptoms. An urticarial rash accompanied nearly 60% of symptomatic episodes of angioedema.


Molecular Genetics

By sequencing the CPN1 gene in genomic DNA extracted from cells of the index patient reported by Mathews et al. (1980), Cao and Hegele (2003) demonstrated that the allergic manifestations in this family were due to presumed compound heterozygosity for 2 mutations in the CPN1 gene (see 603103.0001 and 603103.0002).

In the probands from 4 unrelated families with hereditary angioedema and urticaria, Vincent et al. (2024) identified biallelic mutations in the CPN1 gene. Probands B, C, and D were homozygous for the previously reported missense mutation G178D (603103.0002), whereas the proband in family A was compound heterozygous for G178D and a T245M substitution (603103.0003). Symptomatic family members who were tested were all heterozygous for the G178D mutation. Proband C and her affected mother and sister were also heterozygous for synonymous mutations in the CPN1 gene. In addition, symptomatic individuals in 3 of the families (A, B, and C) were reported to carry 1 or more variants in other kinin-associated genes; the relationship of the variants to the hereditary angioedema phenotypes in those families was unclear.


See Also:

Mathews et al. (1986); Mathews (1986)

REFERENCES

  1. Cao, H., Hegele, R. A. DNA polymorphism and mutations in CPN1, including the genomic basis of carboxypeptidase N deficiency. J. Hum. Genet. 48: 20-22, 2003. [PubMed: 12560874] [Full Text: https://doi.org/10.1007/s100380300003]

  2. Mathews, K. P., Curd, J. G., Hugli, T. E. Decreased synthesis of serum carboxypeptidase N (SCPN) in familial SCPN deficiency. J. Clin. Immun. 6: 87-92, 1986. [PubMed: 3958137] [Full Text: https://doi.org/10.1007/BF00915368]

  3. Mathews, K. P., Pan, P. M., Gardner, N. J., Hugli, T. E. Familial carboxypeptidase N deficiency. Ann. Intern. Med. 93: 443-445, 1980. [PubMed: 7437116] [Full Text: https://doi.org/10.7326/0003-4819-93-3-443]

  4. Mathews, K. P. Deficiencies in regulator proteins. 4. Anaphylatoxin inactivator. Prog. Allergy 39: 344-351, 1986. [PubMed: 3562474]

  5. Vincent, D., Parsopoulou, F., Martin, L., Gaboriaud, C., Demongeot, J., Loules, G., Fischer, S., Cichon, S., Germenis, A. E., Ghannam, A., Drouet, C. Hereditary angioedema with normal C1 inhibitor associated with carboxypeptidase N deficiency. J. Allergy Clin. Immun. Glob. 3: 100223, 2024. Note: Erratum: J. Allergy Clin. Immun. Glob. 3: 100319, 2024. [PubMed: 38445235] [Full Text: https://doi.org/10.1016/j.jacig.2024.100223]


Contributors:
Marla J. F. O'Neill - updated : 09/23/2024
Victor A. McKusick - updated : 2/11/2003
Victor A. McKusick - updated : 2/4/1997

Creation Date:
Victor A. McKusick : 6/3/1986

Edit History:
alopez : 10/01/2024
alopez : 09/23/2024
alopez : 09/23/2024
alopez : 09/23/2024
carol : 02/21/2003
tkritzer : 2/13/2003
terry : 2/11/2003
alopez : 7/27/1999
alopez : 10/8/1998
alopez : 10/8/1998
alopez : 8/18/1998
mark : 2/5/1997
jenny : 2/4/1997
terry : 1/21/1997
mimadm : 2/19/1994
carol : 10/15/1992
carol : 9/4/1992
supermim : 3/16/1992
supermim : 3/20/1990
ddp : 10/26/1989